Confirmed Speakers 2006 already include:

Brian Hargreaves, Sector Partner – Healthcare, 3i
Dennis Purcell, General Partner, Aisling Capital
Mark Chalek, Chief Business Ventures, Director, Technololgy Ventures Office, Beth Israel Deaconess Medical Centre
Dr Lee Nadler, Senior Vice President for Experimental Medicine, Dana Farber Cancer Institute
Marcia Anderegg, Partner, Edwards Angell Palmer & Dodge LLP
Stephem M Muniz, Partner, Edwards Angell Palmer & Dodge LLP
Al Sokol, Partner, Edwards Angell Palmer & Dodge LLP
William C Mills III, Managing Member, EGS Healthcare
Dr O Prem Das, Director, Office of Technology Licensing & Industry Sponsored Research, Harvard Medical School
Stan Yakatan, Chairman, Katan Associates
Donna L LaVoie, President & CEO, LaVoie Strategic Communications Group
Tom Sommer, President, MASSMedic
Dr Evan Facher, Corporate Innovations, MEDRAD, Inc.
Lothar Krinke, Senior Director Business Development, Medtronic Neurological
Dr David Scheinberg, Chairman of the Experimental Therapeutics Center, Memorial Sloan-Kettering Cancer Center
Guy Eiferman, Vice President, Alliance Management, Merck & Co
Prof Frank Douglas, Professor of Practice, MIT, Sloan School of Management
Dr Steven St. Peter, General Partner, MPM Capital
Corinne Savill, Global Head of Search and Evaluation, Business Development and Licensing, Novartis Pharmaceuticals
Michael Lytton, General Partner, Oxford Bioscience Partners
James M. Garvey, CEO & Managing Partner, SV Life Science Advisors
Dr Gert A Caspritz, General Partner, Techno Venture Management
Dr Andrew McDonald, Biotech Analyst, Think Equity
Phil Tinmouth, Senior Director Corporate & Business Development, Vertex Pharmaceuticals
Charles V Baltic III, Managing Director, Healthcare Investment Banking, Wachovia Securities
Jonathan Leff, Managing Director, Warburg Pincus